ARCHIVES

NCI Closes Iressa Trial For NSCLC When Data Indicate No Survival Benefit

This article is from The Cancer Letter archive.

Vol. 28 No. 4 | April 29, 2005

Download PDF Visit The Full Archive

Related Articles

FDA, NCI, CMS Announce Biomarker Initiative; First Project To Validate FDG-PET As Predictor Of Tumor Response In Non-Hodgkin’s Lymphoma.

February 17, 2006

Cancer Telethon Attracts Small Audience, Generates Expectations-And Questions.

September 12, 2008

HHS, NIH Prepare for Government Shutdown

September 20, 2013

Funding Opportunities: Aging Institute Offers Program Announcement

February 6, 1998

Reagan Goes On Record Against Smoking, Dietary Fat

April 22, 1988

Children of Male Cancer Survivors Have Highrt Risk of Birth Defects

February 25, 2011